RGDXQ (Response Genetics) Selling, General, & Admin. Expense: $16.72 Mil (TTM As of Dec. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Response Genetics Selling, General, & Admin. Expense?

Response Genetics RGDXQ -98.00% Selling, General, & Admin. Expense is $16.72 Mil as of Dec. 2015.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Response Genetics's selling, general, & admin. expense for the three months ended in Dec. 2015 was $0.00 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2015 was $16.72 Mil.


Response Genetics  (OTCPK:RGDXQ) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Response Genetics Selling, General, & Admin. Expense Related Terms


Response Genetics Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Response Genetics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics Selling, General, & Admin. Expense Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.27 13.85 7.96 16.33 19.84

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.33 4.80 2.74 4.85 0.00

RGDXQ vs PSID, GBSN, ETAH: Selling, General, & Admin. Expense Comparison

For the Diagnostics & Research subindustry, Response Genetics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Response Genetics Selling, General, & Admin. Expense vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Response Genetics's Selling, General, & Admin. Expense falls into.



Response Genetics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $16.72 Mil mean?
Response Genetics (RGDXQ) has a Selling, General, & Admin. Expense of $16.72 Mil as of Dec. 2015. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Response Genetics and its competitors.
Is Response Genetics' Selling, General, & Admin. Expense too high?
Response Genetics' current Selling, General, & Admin. Expense is $16.72 Mil.
How does Response Genetics' Selling, General, & Admin. Expense compare to PSID and GBSN?
Response Genetics' Selling, General, & Admin. Expense of $16.72 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Diagnostics & Research company?
A good Selling, General, & Admin. Expense depends on the Medical Diagnostics & Research industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Response Genetics and its competitors. Response Genetics's current Selling, General, & Admin. Expense is $16.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Selling, General, & Admin. Expense of $16.72 Mil. The current Selling, General, & Admin. Expense is $16.72 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Selling, General, & Admin. Expense is $16.72 Mil as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.